Nio Vs Rivian Stock, Which EV Is Best?
Nio (NYSE:NIO) and Rivian (NASDAQ:RIVN) are two EV startups that…
Sell
39
ACAD Quote, Financials, Valuation and Earnings
Last price:
$14.64
Seasonality move
:
4.4%
Day range:
$15.28 - $15.97
52-week range:
$14.15 - $20.68
Dividend yield:
0%
P/E ratio:
11.31x
P/S ratio:
2.67x
P/B ratio:
3.50x
Volume:
2.2M
Avg. volume:
1.7M
1-year change:
-14.79%
Market cap:
$2.6B
Revenue:
$957.8M
EPS (TTM):
$1.36
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ACAD
ACADIA Pharmaceuticals
|
$233.6M | -$0.03 | 16.28% | -91.94% | $24.85 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.24 | 14.03% | -95.43% | $0.85 |
|
OGEN
Oragenics
|
-- | -- | -- | -- | $1.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -100% | -67.93% | $7.00 |
|
SWTX
SpringWorks Therapeutics
|
$66.9M | -$0.74 | 218.64% | -37.01% | $72.88 |
|
TOVX
Theriva Biologics
|
-- | -$5.50 | -- | -8.25% | $6.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ACAD
ACADIA Pharmaceuticals
|
$15.38 | $24.85 | $2.6B | 11.31x | $0.00 | 0% | 2.67x |
|
NBY
NovaBay Pharmaceuticals
|
$0.52 | $0.85 | $2.5M | -- | $0.00 | 0% | 0.06x |
|
OGEN
Oragenics
|
$0.19 | $1.00 | $4M | -- | $0.00 | 0% | 1.17x |
|
PTN
Palatin Technologies
|
$0.51 | $7.00 | $13.3M | -- | $0.00 | 0% | -- |
|
SWTX
SpringWorks Therapeutics
|
$39.09 | $72.88 | $2.9B | -- | $0.00 | 0% | 15.13x |
|
TOVX
Theriva Biologics
|
$1.08 | $6.00 | $3M | -- | $0.00 | 0% | 0.63x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ACAD
ACADIA Pharmaceuticals
|
-- | 0.878 | -- | 2.18x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | 0.451 | 1.51% | 0.75x |
|
OGEN
Oragenics
|
-- | 3.461 | -- | -- |
|
PTN
Palatin Technologies
|
-- | 0.220 | -- | 0.99x |
|
SWTX
SpringWorks Therapeutics
|
-- | 1.659 | -- | 3.54x |
|
TOVX
Theriva Biologics
|
-- | -1.635 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ACAD
ACADIA Pharmaceuticals
|
$237.8M | $7M | 41.59% | 41.59% | 2.69% | $39.9M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$1.1M | -334.47% | -461.38% | -44% | -$2.1M |
|
OGEN
Oragenics
|
-- | -$3.4M | -- | -- | -- | -$2M |
|
PTN
Palatin Technologies
|
-- | -$5.1M | -- | -- | -2356.3% | -$4.8M |
|
SWTX
SpringWorks Therapeutics
|
$56M | -$81.3M | -46.69% | -46.69% | -132.16% | -$35.6M |
|
TOVX
Theriva Biologics
|
-- | -$4.6M | -- | -- | -- | -$4.7M |
ACADIA Pharmaceuticals vs. Competitors
-
Which has Higher Returns ACAD or NBY?
NovaBay Pharmaceuticals has a net margin of 55.37% compared to ACADIA Pharmaceuticals's net margin of -49.65%. ACADIA Pharmaceuticals's return on equity of 41.59% beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital ACADACADIA Pharmaceuticals91.6% $0.86 $732.8M NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M -
What do Analysts Say About ACAD or NBY?
ACADIA Pharmaceuticals has a consensus price target of $24.85, signalling upside risk potential of 61.57%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 64.47%. Given that NovaBay Pharmaceuticals has higher upside potential than ACADIA Pharmaceuticals, analysts believe NovaBay Pharmaceuticals is more attractive than ACADIA Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings ACADACADIA Pharmaceuticals6 7 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is ACAD or NBY More Risky?
ACADIA Pharmaceuticals has a beta of 0.537, which suggesting that the stock is 46.313% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.
-
Which is a Better Dividend Stock ACAD or NBY?
ACADIA Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACAD or NBY?
ACADIA Pharmaceuticals quarterly revenues are $259.6M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. ACADIA Pharmaceuticals's net income of $143.7M is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, ACADIA Pharmaceuticals's price-to-earnings ratio is 11.31x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals is 2.67x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACADACADIA Pharmaceuticals2.67x 11.31x $259.6M $143.7M NBYNovaBay Pharmaceuticals0.06x -- $2.4M -$1.2M
-
Which has Higher Returns ACAD or OGEN?
Oragenics has a net margin of 55.37% compared to ACADIA Pharmaceuticals's net margin of --. ACADIA Pharmaceuticals's return on equity of 41.59% beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ACADACADIA Pharmaceuticals91.6% $0.86 $732.8M OGENOragenics-- -$0.27 -- -
What do Analysts Say About ACAD or OGEN?
ACADIA Pharmaceuticals has a consensus price target of $24.85, signalling upside risk potential of 61.57%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 434.19%. Given that Oragenics has higher upside potential than ACADIA Pharmaceuticals, analysts believe Oragenics is more attractive than ACADIA Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings ACADACADIA Pharmaceuticals6 7 0 OGENOragenics0 1 0 -
Is ACAD or OGEN More Risky?
ACADIA Pharmaceuticals has a beta of 0.537, which suggesting that the stock is 46.313% less volatile than S&P 500. In comparison Oragenics has a beta of 0.868, suggesting its less volatile than the S&P 500 by 13.16%.
-
Which is a Better Dividend Stock ACAD or OGEN?
ACADIA Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACAD or OGEN?
ACADIA Pharmaceuticals quarterly revenues are $259.6M, which are larger than Oragenics quarterly revenues of --. ACADIA Pharmaceuticals's net income of $143.7M is higher than Oragenics's net income of -$3.3M. Notably, ACADIA Pharmaceuticals's price-to-earnings ratio is 11.31x while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals is 2.67x versus 1.17x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACADACADIA Pharmaceuticals2.67x 11.31x $259.6M $143.7M OGENOragenics1.17x -- -- -$3.3M
-
Which has Higher Returns ACAD or PTN?
Palatin Technologies has a net margin of 55.37% compared to ACADIA Pharmaceuticals's net margin of -2357.27%. ACADIA Pharmaceuticals's return on equity of 41.59% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ACADACADIA Pharmaceuticals91.6% $0.86 $732.8M PTNPalatin Technologies-- -$0.12 -$111.5K -
What do Analysts Say About ACAD or PTN?
ACADIA Pharmaceuticals has a consensus price target of $24.85, signalling upside risk potential of 61.57%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 1268.52%. Given that Palatin Technologies has higher upside potential than ACADIA Pharmaceuticals, analysts believe Palatin Technologies is more attractive than ACADIA Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings ACADACADIA Pharmaceuticals6 7 0 PTNPalatin Technologies0 0 0 -
Is ACAD or PTN More Risky?
ACADIA Pharmaceuticals has a beta of 0.537, which suggesting that the stock is 46.313% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.
-
Which is a Better Dividend Stock ACAD or PTN?
ACADIA Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACAD or PTN?
ACADIA Pharmaceuticals quarterly revenues are $259.6M, which are larger than Palatin Technologies quarterly revenues of $350K. ACADIA Pharmaceuticals's net income of $143.7M is higher than Palatin Technologies's net income of -$2.4M. Notably, ACADIA Pharmaceuticals's price-to-earnings ratio is 11.31x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals is 2.67x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACADACADIA Pharmaceuticals2.67x 11.31x $259.6M $143.7M PTNPalatin Technologies-- -- $350K -$2.4M
-
Which has Higher Returns ACAD or SWTX?
SpringWorks Therapeutics has a net margin of 55.37% compared to ACADIA Pharmaceuticals's net margin of -125.59%. ACADIA Pharmaceuticals's return on equity of 41.59% beat SpringWorks Therapeutics's return on equity of -46.69%.
Company Gross Margin Earnings Per Share Invested Capital ACADACADIA Pharmaceuticals91.6% $0.86 $732.8M SWTXSpringWorks Therapeutics90.98% -$1.04 $481.1M -
What do Analysts Say About ACAD or SWTX?
ACADIA Pharmaceuticals has a consensus price target of $24.85, signalling upside risk potential of 61.57%. On the other hand SpringWorks Therapeutics has an analysts' consensus of $72.88 which suggests that it could grow by 86.43%. Given that SpringWorks Therapeutics has higher upside potential than ACADIA Pharmaceuticals, analysts believe SpringWorks Therapeutics is more attractive than ACADIA Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings ACADACADIA Pharmaceuticals6 7 0 SWTXSpringWorks Therapeutics5 0 0 -
Is ACAD or SWTX More Risky?
ACADIA Pharmaceuticals has a beta of 0.537, which suggesting that the stock is 46.313% less volatile than S&P 500. In comparison SpringWorks Therapeutics has a beta of 0.787, suggesting its less volatile than the S&P 500 by 21.261%.
-
Which is a Better Dividend Stock ACAD or SWTX?
ACADIA Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SpringWorks Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals pays -- of its earnings as a dividend. SpringWorks Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACAD or SWTX?
ACADIA Pharmaceuticals quarterly revenues are $259.6M, which are larger than SpringWorks Therapeutics quarterly revenues of $61.5M. ACADIA Pharmaceuticals's net income of $143.7M is higher than SpringWorks Therapeutics's net income of -$77.3M. Notably, ACADIA Pharmaceuticals's price-to-earnings ratio is 11.31x while SpringWorks Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals is 2.67x versus 15.13x for SpringWorks Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACADACADIA Pharmaceuticals2.67x 11.31x $259.6M $143.7M SWTXSpringWorks Therapeutics15.13x -- $61.5M -$77.3M
-
Which has Higher Returns ACAD or TOVX?
Theriva Biologics has a net margin of 55.37% compared to ACADIA Pharmaceuticals's net margin of --. ACADIA Pharmaceuticals's return on equity of 41.59% beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ACADACADIA Pharmaceuticals91.6% $0.86 $732.8M TOVXTheriva Biologics-- -$1.60 -- -
What do Analysts Say About ACAD or TOVX?
ACADIA Pharmaceuticals has a consensus price target of $24.85, signalling upside risk potential of 61.57%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 455.56%. Given that Theriva Biologics has higher upside potential than ACADIA Pharmaceuticals, analysts believe Theriva Biologics is more attractive than ACADIA Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings ACADACADIA Pharmaceuticals6 7 0 TOVXTheriva Biologics0 0 0 -
Is ACAD or TOVX More Risky?
ACADIA Pharmaceuticals has a beta of 0.537, which suggesting that the stock is 46.313% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.169, suggesting its more volatile than the S&P 500 by 16.92%.
-
Which is a Better Dividend Stock ACAD or TOVX?
ACADIA Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACAD or TOVX?
ACADIA Pharmaceuticals quarterly revenues are $259.6M, which are larger than Theriva Biologics quarterly revenues of --. ACADIA Pharmaceuticals's net income of $143.7M is higher than Theriva Biologics's net income of -$4.4M. Notably, ACADIA Pharmaceuticals's price-to-earnings ratio is 11.31x while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals is 2.67x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACADACADIA Pharmaceuticals2.67x 11.31x $259.6M $143.7M TOVXTheriva Biologics0.63x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Sweetgreen Stock Worth Holding For the Next Five Years?
Sweetgreen (NYSE:SG) is an up-and-coming quick service restaurant chain focused…
What Do I Need to Know About Alcoa Stock?
Alcoa (AA) is a global leader in aluminum production. Based…
Stock Ideas
Sell
37
Is AAPL Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 31x
Sell
37
Is MSFT Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 30x
Sell
31
Is NVDA Stock a Buy?
Market Cap: $2.3T
P/E Ratio: 32x
Alerts
Sell
25
GDXU alert for Apr 7
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 1.93% over the past day.
Buy
76
SOXS alert for Apr 7
Direxion Daily Semiconductor Bear 3X Shares [SOXS] is down 7.07% over the past day.
Sell
15
FAS alert for Apr 7
Direxion Daily Financial Bull 3x Shares [FAS] is down 0.96% over the past day.
